Increased bone mass in mice lacking the adipokine apelin

Endocrinology

Volumn 154, Issue 6, 2013, Pages 2069-2089

  Wattanachanya, Lalita ^a,b   Lu, Wei Dar ^a   Kundu, Ramendra K ^c   Wang, Liping ^a,b   Abbott, Marcia J ^a   O'Carroll, Dylan ^a   Quertermous, Thomas ^c   Nissenson, Robert A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; APELIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE CELL; BONE MASS; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; FEMALE; FEMUR; IN VIVO STUDY; INSULIN SENSITIVITY; KNOCKOUT MOUSE; MALE; MICRO-COMPUTED TOMOGRAPHY; MINERAL METABOLISM; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; PARACRINE SIGNALING; PERIMETER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; TRABECULAR BONE;

ADIPOKINES; ANIMALS; APOPTOSIS; BONE DENSITY; CELL PROLIFERATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; FEMUR; GENE EXPRESSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIBIA; TRANSCRIPTION FACTORS; X-RAY MICROTOMOGRAPHY;

EID: 84878445754     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2034     Document Type: Article

References (53)

1. Reid IR. Relationships between fat and bone. Osteoporos Int. 2008;19:595-606. (Pubitemid 351642171)
2. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471-476. (Pubitemid 28505047)
3. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International union of basic and clinical pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62:331-342.
4. Carpéné C, Dray C, Attané C, et al. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem. 2007;63:359-373.
5. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233-240. (Pubitemid 40128188)
6. Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-1172. (Pubitemid 36330668)
7. O'Carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta. 2000;1492:72-80. (Pubitemid 30349182)
8. Ashley E, Chun HJ, Quertermous T. Opposing cardiovascular roles for the angiotensin and apelin signaling pathways. J Mol Cell Cardiol. 2006;41:778-781. (Pubitemid 44635576)
9. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol. 2006;296:177-189. (Pubitemid 44061763)
10. Reaux A, De Mota N, Skultetyova I, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem. 2001;77:1085-1096. (Pubitemid 32467063)
11. Taheri S, Murphy K, Cohen M, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun. 2002;291:1208-1212. (Pubitemid 34694318)
12. Atluri P, Morine KJ, Liao GP, et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett. 2007;12:127-138. (Pubitemid 46786647)
13. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006;553:222-228. (Pubitemid 44779594)
14. Foussal C, Lairez O, Calise D, et al. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett. 2010;584:2363-2370.
15. Francia P, Salvati A, Balla C, et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail. 2007;9:306-309. (Pubitemid 46343708)
16. Pchejetski D, Foussal C, Alfarano C, et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2012;33(18):2360-2369.
17. Tao J, Zhu W, Li Y, et al. Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol. 2011;301:H1471-H1486.
18. Goetze JP, Rehfeld JF, Carlsen J, et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept. 2006;133:134-138. (Pubitemid 41820346)
19. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764-1771. (Pubitemid 40396885)
20. Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001;1538:162-171. (Pubitemid 32402239)
21. Castan-Laurell I, Dray C, Knauf C, Kunduzova O, Valet P. Apelin, a promising target for type 2 diabetes treatment? Trends Endocrinol Metab. 2012;23:234-241.
22. Castan-Laurell I, Vítkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008;158:905-910. (Pubitemid 351837380)
23. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg. 2009;19:1574-1580.
24. Yue P, Jin H, Xu S, et al. Apelin decreases lipolysis via G(q), G(i), and AMPK-dependent mechanisms. Endocrinology. 2011;152:59-68.
25. Yue P, Jin H, Aillaud M, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;298:E59-E67.
26. Attané C, Foussal C, Le Gonidec S, et al. Apelin treatment increases complete fatty acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes. 2012;61:310-320.
27. Tang SY, Xie H, Yuan LQ, et al. Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. Peptides. 2007;28:708-718. (Pubitemid 46204990)
28. Xie H, Tang SY, Cui RR, et al. Apelin and its receptor are expressed in human osteoblasts. Regul Pept. 2006;134:118-125.
29. Zhang H, Xie H, Zhao Q, et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest. 2010;33:707-711.
30. Xie H, Yuan LQ, Luo XH, et al. Apelin suppresses apoptosis of human osteoblasts. Apoptosis. 2007;12:247-254. (Pubitemid 46009517)
31. Charo DN, Ho M, Fajardo G, et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol. 2009;297:H1904-H1913.
32. Iwaniec UT, Yuan D, Power RA, Wronski TJ. Strain-dependent variations in the response of cancellous bone to ovariectomy in mice. J Bone Miner Res. 2006;21:1068-1074. (Pubitemid 43962835)
33. Kalajzic I, Kalajzic Z, Kaliterna M, et al. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J Bone Miner Res. 2002;17:15-25. (Pubitemid 33150992)
34. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004;19:235-244. (Pubitemid 38116737)
35. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473:139-146.
36. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231-1234.
37. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17:1235-1241.
38. Williams GA, Wang Y, Callon KE, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology. 2009;150:3603-3610.
39. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331:520-526. (Pubitemid 40602668)
40. Cirmanova V, Bayer M, Starka L, Zajickova K. The effect of leptin on bone: an evolving concept of action. Physiol Res. 2008;57(suppl 1):S143-S151.
41. Williams GA, Callon KE, Watson M, et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res. 2011;26:1698-1709.
42. Millard SM, Louie AM, Wattanachanya L, Wronski TJ, Conklin BR, Nissenson RA. Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation. J Bone Miner Res. 2011;26:822-832.
43. Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544-548. (Pubitemid 46087259)
44. Sörhede Winzell M, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept. 2005;131:12-17.
45. Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept. 2005;132:27-32. (Pubitemid 41607499)
46. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation In vivo. Calcif Tissue Int. 1996;59:492-495. (Pubitemid 26397171)
47. Yang J, Zhang X, Wang W, Liu J. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell Biochem Funct. 2010;28:334-341.
48. Fujiwara N, Tabata MJ, Endoh M, Ishizeki K, Nawa T. Insulin-like growth factor-I stimulates cell proliferation in the outer layer of Hertwig's epithelial root sheath and elongation of the tooth root in mouse molars in vitro. Cell Tissue Res. 2005;320:69-75. (Pubitemid 40543763)
49. Pun KK, Lau P, Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res. 1989;4:853-862. (Pubitemid 20065695)
50. Daviaud D, Boucher J, Gesta S, et al. TNFα up-regulates apelin expression in human and mouse adipose tissue. FASEB J. 2006;20:1528-1530.
51. Han S, Wang G, Qi X, Englander EW, Greeley GH Jr. Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1068-G1078.
52. Leeper NJ, Tedesco MM, Kojima Y, et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol. 2009;296:H1329-H1335.
53. Reaux-Le Goazigo A, Alvear-Perez R, et al. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. Am J Physiol Endocrinol Metab. 2007;292:E7-E15. (Pubitemid 46070109)